TEVA+4%/REGN+2% on Fasinumab nominally-positive phase-3 data in OA: https://www.businesswire.com/news/home/20180816005225/en/Teva-Regeneron-Announce-Positive-Topline-Phase-3 http://www.evaluate.com/vantage/articles/news/snippets/not-so-fast-fasinumab-celebrations